Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: J Hypertens. 2012 Jan;30(1):87–96. doi: 10.1097/HJH.0b013e32834dde5f

Fig. 1.

Fig. 1

Telmisartan (Telm) inhibited lipopolysaccharide (LPS)-induced pro-inflammatory cytokine release and mRNA expression in human monocytes. Monocytes were incubated with 50 ng/ml LPS alone or after 2 h pre-incubation with different doses of Telm. (a) Cumulative release of pro-inflammatory cytokines 4 h after LPS addition as determined by ELISA. (b) Expression of cytokine mRNA after 2 h incubation with LPS as determined by real-time PCR. Results are means ± SEM from three independent experiments and are expressed as a percentage of LPS-induced response. IL, interleukin; TNF, tumor necrosis factor. #P<0.05; ##P<0.01; ###P<0.001 compared with LPS.